BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer. METHODS: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy. RESULTS: A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).
BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced rectal cancer. METHODS: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair-deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy. RESULTS: A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported. CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.).
Authors: Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz Journal: N Engl J Med Date: 2020-12-03 Impact factor: 91.245
Authors: Samantha K Hendren; Brenda I O'Connor; Maria Liu; Tracey Asano; Zane Cohen; Carol J Swallow; Helen M Macrae; Robert Gryfe; Robin S McLeod Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: K C M J Peeters; C J H van de Velde; J W H Leer; H Martijn; J M C Junggeburt; E Klein Kranenbarg; W H Steup; T Wiggers; H J Rutten; C A M Marijnen Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: J B Reese; P H Finan; J A Haythornthwaite; M Kadan; K R Regan; J M Herman; J Efron; L A Diaz; N S Azad Journal: Support Care Cancer Date: 2013-10-05 Impact factor: 3.603
Authors: Olusegun Isaac Alatise; Gregory C Knapp; Avinash Sharma; Walid K Chatila; Olukayode A Arowolo; Olalekan Olasehinde; Olusola C Famurewa; Adeleye D Omisore; Akinwumi O Komolafe; Olaejinrinde O Olaofe; Aba I Katung; David E Ibikunle; Adedeji A Egberongbe; Samuel A Olatoke; Sulaiman O Agodirin; Olusola A Adesiyun; Ademola Adeyeye; Oladapo A Kolawole; Akinwumi O Olakanmi; Kanika Arora; Jeremy Constable; Ronak Shah; Azfar Basunia; Brooke Sylvester; Chao Wu; Martin R Weiser; Ken Seier; Mithat Gonen; Zsofia K Stadler; Yelena Kemel; Efsevia Vakiani; Michael F Berger; Timothy A Chan; David B Solit; Jinru Shia; Francisco Sanchez-Vega; Nikolaus Schultz; Murray Brennan; J Joshua Smith; T Peter Kingham Journal: Nat Commun Date: 2021-11-24 Impact factor: 14.919
Authors: Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton Journal: Science Date: 2016-03-03 Impact factor: 47.728
Authors: J Joshua Smith; Oliver S Chow; Marc J Gollub; Garrett M Nash; Larissa K Temple; Martin R Weiser; José G Guillem; Philip B Paty; Karin Avila; Julio Garcia-Aguilar Journal: BMC Cancer Date: 2015-10-23 Impact factor: 4.430
Authors: Miriam R Fernandes; Poonam Aggarwal; Raquel G F Costa; Alicia M Cole; Giorgio Trinchieri Journal: Nat Rev Cancer Date: 2022-10-17 Impact factor: 69.800